Genotypes in the CCL5/CCR5 gene can identify specific populations that would benefit from bevacizumab (BEV: the first anti-angiogenic agent targeting VEGF-A that has been widely used in a variety of cancer types, including mCRC) in the first-line treatment of patients with mCRC. This evidence concerns the gene CCL5 and cancer.